Biosimilar Newsletter Archive

  1. 06.07.19 -- Do You Have The Right Tools To Determine CQA?
    6/7/2019
    06/07/19 Biosimilar Development Newsletter
  2. 06.06.19 -- Biosimilars In MENA: What To Know
    6/6/2019
    06/06/19 Biosimilar Development Newsletter
  3. 05.30.19 -- What To Know About FDA's Interchangeability Guidance
    5/30/2019
    05/30/19 Biosimilar Development Newsletter
  4. 05.23.19 -- 4 Takeaways From The FDA's Biosimilar Insulin Hearing
    5/23/2019
    05/23/19 Biosimilar Development Newsletter
  5. 05.21.19 -- Strategies For The Future Of Biopharma
    5/21/2019
    05/21/19 Biosimilar Development Newsletter
  6. 05.16.19 -- The Purple Book: A Challenge For FDA, Biosimilar Makers?
    5/16/2019
    05/16/19 Biosimilar Development Newsletter
  7. 05.09.19 -- Biosimilar Trastuzumab Market: What You Need To Know
    5/9/2019
    05/09/19 Biosimilar Development Newsletter
  8. 05.02.19 -- USPTO Revisions: Helpful Or Harmful For Biosimilars?
    5/2/2019
    05/02/19 Biosimilar Development Newsletter
  9. 04.25.19 -- Why Biologics Site Of Care Deserves Your Attention
    4/25/2019
    04/25/19 Biosimilar Development Newsletter
  10. 04.23.19 -- Addressing The Challenges Of Next-Generation Biotherapeutics
    4/23/2019
    04/23/19 Biosimilar Development Newsletter